Check out the companies making headlines before the bell. Grail — Shares cratered 47% after the company said a trial of one of its drugs missed its primary endpoint and failed to show statistically significant Stage III-IV cancer reduction. Blue Owl Capital — Shares slid nearly 3%, a day after after the private market and […]
Read More